some patients. Two patients with FAB subtype M3 received
Introduction
Multidrug resistance (MDR) is an important type of cellular drug resistance in acute myeloid leukemia (AML) and is due in Leukemic cells part to overexpression of the MDR1 gene or the MRP gene. [1] [2] [3] [4] [5] The MDR1 gene codes for P-glycoprotein (P-gp) and the MRP Leukemic cells were isolated from either peripheral blood gene for the multidrug resistance-associated protein (MRP). 1, 3 (n = 10), bone marrow aspirates (n = 19) or both sources P-gp is thought to confer drug resistance via an active pump (n = 9) by Ficoll-Paque (Pharmacia, Vienna, Austria) gradient mechanism although other mechanisms are discussed. 6, 7 The centrifugation. Smears were prepared and stored at −70°C exact mechanism by which MRP mediates drug resistance until use. remains to be determined. However, both proteins are Cytospins of C1 and T5 cells were kindly provided by Drs involved in drug transport, thereby decreasing the activity of SPC Cole and RG Deeley (Queen's University, Kingston, many anticancer drugs. MDR1 RNA and P-gp expression have Canada). 28 Drug-sensitive KB-3-1 and multidrug-resistant KBbeen seen in 38-71% and 30-58% of AML patients, and both 8-5 cells (provided by Drs I Pastan and MM Gottesman, parameters predict for poor clinical outcome. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] MRP gene National Cancer Institute, Bethesda, MD, USA) were grown overexpression is also observed in 7-30% of patients. [19] [20] [21] [22] [23] [24] [25] [26] [27] as described. 9 Although a few reports suggest an impact of the MRP gene on clinical outcome, [21] [22] [23] we did not observe a relationship of the expression of this gene to outcome of either induction chemoMonoclonal antibodies therapy or survival of patients.
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The methods applied in order to detect the expression of Two anti-P-gp antibodies, C219 (CIS, Gif-sur-Yvette, France) either MRP or MDR1 genes might affect the results with regard and MRK16 (Kamiya, Tukwila, WA, USA), were used to detect to both frequency and intensity of expression of both genes the expression of P-gp. These two antibodies recognize differand, therefore, might contribute to differences among various ent epitopes of P-gp. MRK16 reacts specifically with a surface studies. To evaluate further this possibility, we immunocytoepitope of human P-gp, whereas C219 recognizes a cytoplasmatic epitope of P-gp and cross-reacts with the MDR2 gene product 29 as well as myosin. 30 Anti-MRP-antibodies To ensure specificity of staining, several controls were perfour (20%) samples, by means of QCRL-3 in four (20%), 12 (60%) and four (20%) samples, and by means of MRPr1 in formed. Firstly, C1 and T5 cells were used as negative and positive controls for MRP expression. 28 Drug-sensitive KB-3-1 three (15%), 16 (80%) and one (5%) samples (Table 2) . P-gp expression was determined by means of either C219 and multidrug-resistant KB-8-5 cells were chosen as negative and positive controls for P-gp expression, respectively. 9 Secor MRK16. C219 staining was low, intermediate and high in three (14%), 15 (72%) and three (14%) samples. MRK16 ondly, negative controls for each sample were performed as described above but without primary antibodies. Thirdly, revealed low, intermediate and high expression in five (24%), 15 (71%) and one (5%) specimens (Table 3) . staining with irrelevant isotype-matched antibodies was performed as negative control in some cases.
Next, the expression levels obtained by the QCRL-1/QCRL-3 combination were compared with those obtained by MRPr1 With regard to both MRP and P-gp, the degree of expression was divided according to the frequency of reactivity into low in 20 cases (Table 4) . Results were consistent in 13 patients and differed by one expression level in six patients. In the case (р5%), intermediate (++; 6-20%) and high (+++; Ͼ20%) expression levels.
of P-gp, the results between C219 and MRK16 were identical in 15 out of 21 patients and in the remaining six patients the expression differed by only one level (Table 4) . Statistical analysis by Weighted Kappa correlation coefficients revealed Statistical analysis that the correlation was fair between MRPr1 and the QCRL-1/QCRL-3 combination (r = 0.36), and moderate between Correlation among different antibodies was estimated using the Weighted Kappa correlation coefficients. Results at the MRK16 and C219 (r = 0.42). time of diagnosis were compared with those at relapse by means of the Wilcoxon rank sum test and results obtained by Table 2 Comparison of MRP expression obtained with various sequential analysis were compared with the Wilcoxon signed antibodies rank test.
No. of Expression levels samples

Results
р5%
++ +++
MRP expression of leukemic cell populations obtained from
either peripheral blood (n = 19) or bone marrow (n = 28) was nation of monoclonal antibodies QCRL-1 and QCRL-3. respectively (Table 1) . High MRP expression was seen in 47% ipheral blood (n = 10) or bone marrow (n = 10). Samples were (15%), 10 (50%) and seven (35%) of the samples, respectively case of C219, the percentage of high expression was similar BM 11 0 (0) 10 (91) 1 (9) to our previous studies with C219 14, 27 but, in the case of MRK16, lower in comparison to Campos et al 11 
who found
Numbers in parentheses refer to percentages.
47% P-gp positive specimens (Ͼ20% staining cells).
P-gp expression was assessed by means of either C219 or MRK16
Direct comparison of the results obtained with the different as described in Materials and methods.
antibodies revealed a fair correlation between MRPr1 and the PB, peripheral blood; BM, bone marrow.
QCRL-1/QCRL-3 combination and a moderate correlation between C219 and MRK16 ( Table 4 ). The latter finding is interesting in the context that the recent recommendations 
used to detect MRP or P-gp in AML might be of less importance than assumed by some investigators in the field. In a 
MRK16
results.
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Consistent with the correlation between C219 and MRK16,
studies with either of these antibodies have been able to demonstrate the negative impact of P-gp expression on clinical
C219
outcome. [11] [12] [13] [14] 27 Since MDR1 RNA expression and functional р5% (n = 3) 2 1 0 assays also predict for clinical outcome, 16, 17 it is currently
unknown which of these tests is most suitable for use in clini-
cal routine. For this purpose, assays not only have to be reliable but must also be feasible on a daily schedule. The
Statistical analysis (Weighted Kappa correlation coefficients)
latter requirement is particularly fulfilled by immunocytorevealed a fair correlation between MRPr1 and QCRL-1/QCRL-3 chemical techniques.
and a moderate correlation between C219 and MRK16.
In the case of MRP, high MRP expression obtained with QCRL-1/QCRL-3 did not predict for either response to induction chemotherapy or survival of patients, 27 and no correThe impact of sample source with regard to MRP or P-gp expression was also studied. For this purpose, a comparison of sponding studies using the MRPr1 antibody have been reported to date. These data are consistent with those obtained expression between peripheral blood blasts and bone marrow blasts was done in nine patients. Although differences with RNA techniques. No correlation was observed between MRP RNA expression and response to chemotherapy in 43 between both sources were seen in 22 out of 51 cases, the differences were usually not more than one level (Table 5) .
patients including 14 relapsed patients 24 and in a second study on 24 patients. 25 Although MRP RNA overexpression Finally, the impact of disease status on MRP expression was studied. When MRP expression at diagnosis was related to the was more frequent in drug-refractory than in drug-sensitive patients in two recent studies, the differences observed did not expression at relapse, the percentages of low, intermediate and high expression were similar between these two disease reach the level of statistical significance. 21, 22 The comparison of MRP or P-gp expression between perstages (Table 6) . A sequential analysis of MRP expression was possible in 13 patients ( Table 7) . As compared to onset, ipheral blood blasts and bone marrow blasts revealed that the expression between both sources was either identical (in the expression levels at relapse were similar in five patients, increased in six patients and decreased in two patients majority of cases) or different by usually not more than one expression level (Table 5 ). In our previous study on the clini- (Table 7) .
cal significance of P-gp, 14 the lower expression level was chosen for analysis in those cases where discrepant results from both sources were observed.
Discussion
In relapsed AML, MRP expression was higher than at the time of diagnosis in four studies, [23] [24] [25] [26] although a statistical sigIn the present study, we determined the expression of the MRP gene and the MDR1 gene by different monoclonal antibodies.
nificant difference was observed in only two of those studies. 24, 26 In our study, the degrees of MRP expression at onset High MRP expression of leukemic cells was found in 5-35% Table 5 Comparison of expression between peripheral blood and bone marrow In nine patients, MRP and P-gp expression determined with different antibodies was compared between peripheral blood blasts and bone marrow blasts. PB, peripheral blood; BM, bone marrow; ND, not determined.
Table 7
Sequential MRP expression Table 6 MRP expression at diagnosis, relapse or drug-refractoriness (A were similar to the degrees of expression at relapse. However, an evaluation of sequential MRP expression in 13 patients
revealed an increase of expression at relapse in six patients р5% (n = 6) 2 2 2 suggesting a tendency towards higher expression at relapse as ++ (n = 5) 1 2 2 +++ (n = 2) 0 1 1 compared to onset. Thus, this possibility will have to be studied further on a representative patient population.
In 13 patients, MRP expression was determined by means of the
In conclusion, both the type of antibodies and the sample QCRL-1/QCRL-3 combination both at diagnosis and at relapse.
source occasionally affected results on the expression of MRP
Results for all patients are shown in (A) and summarized in (B).
or P-gp, but the clinical significance of these differences will
Statistical analysis revealed no significant difference between have to be assessed in a comparative trial on a representative expression at onset and expression at relapse (Wilcoxon signed patient population.
rank test: P = 0.26). Numbers in parentheses refer to percentages of staining blasts. PB, peripheral blood; BM, bone marrow.
